| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Burning Rock Biotech Limited American Depositary Shares
$10
-0.44 (-4.21%)
Market Cap
88.14 M
EPS
-0.72
P/E Ratio
-
Value Trade
229.34 K
8.11 %
Week
8.81 %
1 Month
-0.99 %
3 Month
-58.09 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
6.34 K
52 Week Range
6.79 - 41.72
% held by Insiders
0.24 %
% held by Institutions
19.68 %
Enterprise Value
107.92 M
Total Shares
8.81 M
Short %
0.45 %
Float Shares
9.01 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BNR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BNR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-BNR
Jun 9, 2026▼ -9.8%on this news
Burning Rock Reports First Quarter 2026 Financial Results
Burning Rock Biotech Limited reported its financial results for Q1 2026, showing an 18.9% decrease in revenue compared to the same period in 2025. The company highlighted promising study results at the AACR 2026, but faced challenges with declining revenues in its central laboratory and pharma research services. Despite a slight improvement in gross margins for certain segments, the overall net loss increased.
Read more →-BNR
Mar 12, 2026Burning Rock Reports Unaudited Fourth Quarter and Full Year 2025 Financial Results
Burning Rock Biotech Limited reported its unaudited financial results for the fourth quarter and full year of 2025. Revenue for Q4 2025 was RMB 126.3 million, stable compared to the previous year, while gross profit saw a significant increase. Operating expenses were reduced notably due to cost control measures. Overall, while the company continued to report a net loss, the losses were considerably smaller than in the previous year, indicating improvements in operational efficiency.
Read more →-BNR
Jan 5, 2026▲ +24.4%on this news
Burning Rock Announces Founder’s Purchase of Its ADSs
Burning Rock Biotech Limited announced that its founder and CEO, Mr. Yusheng Han, has purchased over $811,000 worth of the company's American Depositary Shares (ADSs) from the open market. This purchase is seen as a sign of confidence in the company's business prospects. Mr. Han may continue to acquire more ADSs depending on market conditions and regulatory compliance.
Read more →-BNR
Dec 23, 2025▼ -6.9%on this news
Burning Rock Announces Results of 2025 Annual General Meeting
Burning Rock Biotech Limited announced the successful passing of all shareholder resolutions at its 2025 annual general meeting. This indicates strong support from shareholders for the company's strategies and goals. The company is focused on next generation sequencing technology in precision oncology and has made significant progress in cancer early detection advancements. This meeting reflects the commitment of the company to its mission of utilizing science to enhance life.
Read more →-BNR
Dec 1, 2025▼ -12%on this news
Burning Rock Announces 2025 Annual General Meeting to be Held on December 23, 2025
Burning Rock Biotech Limited has announced its Annual General Meeting (AGM) will take place on December 23, 2025, at its Shanghai office. The board of directors supports the proposals to be voted on during the meeting. Shareholders must be recorded by December 1, 2025, to participate. The company has also filed its annual report with the SEC.
Read more →-BNR
Nov 20, 2025Burning Rock Reports Third Quarter 2025 Financial Results
Burning Rock Biotech Limited reported its financial results for Q3 2025, indicating total revenues of RMB131.6 million, a 2.3% increase over the previous year. Operating expenses decreased by 11.9%, resulting in a gross profit increase of 7.6% to RMB98.8 million. Despite the net loss of RMB16.8 million, which is lower than last year, the company continues to focus on precision oncology with its next-generation sequencing technology.
Read more →-BNR
Sep 8, 2025▲ +9.2%on this news
Burning Rock Reports Second Quarter 2025 Financial Results
Burning Rock Biotech Limited has reported its financial results for the second quarter of 2025, showing a revenue increase of 9.6% year-over-year to RMB148.5 million. Gross profit also rose by 13.3%, leading to a gross margin of 72.8%. Significant operating cost-cutting measures led to a 42.1% fall in operating expenses from the previous year. However, the company reported a net loss of RMB9.7 million in the quarter, leading to a mixed outlook despite positive revenue growth.
Read more →-BNR
Jun 6, 2025Burning Rock Reports First Quarter 2025 Financial Results
Burning Rock Biotech Limited (NASDAQ: BNR) reported its financial results for Q1 2025, showing positive growth in revenues and gross profit. The company's revenues reached RMB133.1 million, marking a 5.9% increase from the previous year. Gross profit improved by 13.7%, while gross margins also rose to 73.2%. Operating expenses saw a significant decrease due to cost-control measures, which contributed to enhanced operational efficiency.
Read more →-BNR
Mar 25, 2025▼ -12.4%on this news
Burning Rock Reports Unaudited Fourth Quarter and Full Year 2024 Financial Results
Burning Rock Biotech Limited reported its unaudited financial results for the fourth quarter and full year of 2024. The company experienced a 4.1% increase in revenue for Q4 compared to the same period in 2023, alongside a 14.5% rise in gross profit. However, total revenue for the full year declined by 4.0% from the previous year. The company successfully reduced operating expenses significantly, reflecting a focused effort on cost management despite a continued net loss.
Read more →-BNR
Dec 31, 2024Burning Rock Announces Results of 2024 Annual General Meeting
Burning Rock Biotech Limited has announced the results from its 2024 annual general meeting, where all proposed shareholder resolutions were successfully passed. The company continues to focus on innovative applications of next generation sequencing technology, specifically within precision oncology. Its advancements have moved from proof-of-concept research and development to the clinical validation stage, suggesting a positive trajectory for its NGS-based therapy and early cancer detection services.
Read more →-BNR
Dec 4, 2024▲ +13.7%on this news
Burning Rock Reports Third Quarter 2024 Financial Results
Burning Rock Biotech Limited reported its financial results for Q3 2024, highlighting a slight revenue increase to RMB128.6 million. The company saw a significant improvement in gross margin and reduced operating expenses by over 50% compared to the previous year. However, the business is experiencing a shift from central-lab to in-hospital testing, which impacted revenues in its central laboratory segment. Despite a net loss of RMB35.7 million, this figure marks a notable improvement from the same period in 2023.
Read more →-BNR
Dec 3, 2024Burning Rock Announces 2024 Annual General Meeting to be Held on
Burning Rock Biotech Limited has announced its Annual General Meeting (AGM) scheduled for December 31, 2024, in Shanghai. Shareholders of the company's Class A and Class B ordinary shares will be able to attend and vote on proposed resolutions. The company has also filed its annual report for the year ended December 31, 2023, with the SEC, which is accessible online. The AGM reflects the company's commitment to transparency and shareholder engagement.
Read more →-BNR
Sep 27, 2024Burning Rock Announces Changes to Management and Board of Directors
Burning Rock Biotech Limited announced changes in its management and board of directors, including the resignation of Mr. Leo Li. His departure, effective September 27, 2024, was for personal reasons and not due to any disagreements. Ms. Xiaozhi Hu will now oversee financial operations, having been with the company since 2014. The company's chairman acknowledged Mr. Li's contributions to key developments, including the initial public offering.
Read more →-BNR
Aug 23, 2024▼ -6.8%on this news
Burning Rock Reports Second Quarter 2024 Financial Results
Burning Rock Biotech Limited reported its financial results for the second quarter of 2024, indicating a decrease in total revenue to RMB135.5 million, down 7.3% from the previous year. Despite this, the in-hospital segment continued to exhibit robust double-digit growth. The company's gross margin improved to 70.4%, and operating expenses were notably reduced by 12.5%, reflecting effective budget management. However, the net loss widened compared to the same period last year, signaling ongoing challenges in achieving profitability.
Read more →-BNR
Jun 3, 2024Burning Rock Regains Compliance with NASDAQ Minimum Bid Price Requirement
Burning Rock Biotech Limited has announced that it has regained compliance with NASDAQ's minimum bid price requirement after receiving notification on May 30, 2024. The company had previously struggled with share prices falling below the required $1.00 for 30 consecutive business days. To address this issue, Burning Rock adjusted the ratio of its American depositary shares, which became effective on May 15, 2024. Following this change, the company's shares have remained above the minimum bid price for the required duration, allowing it to close the compliance matter with NASDAQ.
Read more →-BNR
May 29, 2024Burning Rock Reports First Quarter 2024 Financial Results
Burning Rock Biotech Limited reported its financial results for the first quarter of 2024, showing an 11.9% decrease in total revenues compared to the previous year. While the in-hospital testing segment continued to grow, overall revenues were negatively impacted by a shift away from central lab operations. The company saw a reduction in operating expenses and maintained a substantial cash reserve. Despite a reduced net loss, challenges remain in achieving positive growth in various segments.
Read more →-BNR
May 15, 2024Burning Rock Announces ADS Ratio Change to Be Effective on
Burning Rock Biotech Limited announced a change in its American depositary shares (ADS) ratio, effective May 15, 2024. The new ratio will be one ADS representing ten Class A ordinary shares, resulting in a reverse ADS split. While the ADS price is expected to increase proportionally, the company cannot guarantee that it will reach or exceed ten times the previous price. This change is designed to streamline trading for existing shareholders.
Read more →-BNR
Apr 26, 2024Burning Rock Announces ADS Ratio Change
Burning Rock Biotech Limited announced a modification in its American depositary shares (ADS) ratio, transitioning from one ADS for one Class A ordinary share to one ADS for ten shares. This change, set to take effect around May 15, 2024, is likened to a one-for-ten reverse split. While the company anticipates a proportional increase in ADS prices, it does not guarantee that the post-change price will be at least ten times the previous price. The company continues to focus on next generation sequencing technology in precision oncology, with ongoing efforts in therapy selection testing and cancer detection.
Read more →-BNR
Mar 29, 2024Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results
Burning Rock Biotech Limited reported its financial results for the fourth quarter and full year of 2023, highlighting a decline in revenues and gross profits compared to previous periods. Specifically, fourth quarter revenues fell by 14.9% year-over-year, while the full year revealed a 4.6% revenue decrease. Despite cost-cutting measures that led to a reduction in operating expenses, the company still faced a net loss of RMB653.7 million for 2023. Management expects to reach breakeven in the first half of 2024, but the latest results indicate ongoing financial struggles.
Read more →-BNR
Jan 4, 2024Burning Rock Announces Receipt of Notification from
Burning Rock Biotech Limited has received notification from NASDAQ indicating that its American depositary shares (ADSs) closed below the minimum bid price of $1.00 for 30 consecutive business days. The company is granted a compliance period of 180 days to regain compliance by achieving a closing bid price of at least $1.00 for 10 consecutive business days. Alternatively, if it fails to comply by the deadline, the company may qualify for an additional 180 days. The notification does not affect the company's business operations or trading of its securities.
Read more →-BNR
Dec 20, 2023Burning Rock Announces Results of 2023 Annual General Meeting
Burning Rock Biotech Limited announced that all resolutions proposed at its 2023 annual general meeting were successfully passed. The company, focused on next generation sequencing technology in precision oncology, is progressing from proof-of-concept R&D to the clinical validation stage. This reflects its commitment to enhancing cancer detection and therapy selection for late-stage patients.
Read more →-BNR
Nov 30, 2023▼ -7.3%on this news
Burning Rock Reports Third Quarter 2023 Financial Results
Burning Rock Biotech Limited reported financial results for Q3 2023, with revenues totaling RMB127.6 million, marking a 17.5% decrease year-over-year. Operating expenses were reduced by 22.9%, contributing to a decreased net loss of RMB175.0 million compared to the previous year. However, the company faced challenges as gross profit declined by 20.9%, highlighting ongoing operational difficulties while maintaining substantial cash reserves.
Read more →-BNR
Nov 22, 2023Burning Rock Announces 2023 Annual General Meeting to be Held on
Burning Rock Biotech Limited has announced its Annual General Meeting (AGM) scheduled for December 20, 2023, in Shanghai. The record date for shareholders entitled to attend the meeting is set for November 22, 2023. During the meeting, the board will address various proposals, and details of the meeting can be found on the company's Investor Relations website. The company emphasizes its focus on next generation sequencing technology in oncology, marking its progression from R&D to clinical validation.
Read more →-BNR
Aug 31, 2023Burning Rock Reports Second Quarter 2023 Financial Results
Burning Rock Biotech Limited reported its financial results for the second quarter of 2023, showcasing a revenue increase of 11.8% to RMB146.3 million and a gross profit rise of 21.6%, enhanced by improved gross margins across various business channels. Operating expenses also decreased notably by 32.2%, indicating effective cost control measures. However, the company still faced a net loss of RMB131.2 million, underscoring the challenges in achieving profitability amidst growing revenues.
Read more →-BNR
Jun 28, 2023Burning Rock Announces Resignation and Appointment of Directors
Burning Rock Biotech Limited announced the resignation of Dr. Shaokun (Shannon) Chuai as a director and Chief Scientific Officer, effective June 30, 2023. Dr. Chuai will remain a senior advisor while Dr. Zhihong (Joe) Zhang will join the Board as a new director. The company acknowledged Dr. Chuai's significant contributions over her tenure, during which she played a key role in the development of various genomic profiling products. Both parties expressed confidence in the future direction of Burning Rock.
Read more →-BNR
May 30, 2023Burning Rock Reports First Quarter 2023 Financial Results
Burning Rock Biotech Limited reported its financial results for the first quarter of 2023, evidencing a 5.2% increase in revenues, amounting to RMB142.5 million. The company's gross profit also rose 12.8% year-over-year, reflecting a gross margin of 69.3%. Operating expenses were reduced by 18% due to better budget management and workforce adjustments. However, the company still reported a significant net loss of RMB185.3 million, albeit an improvement from the previous year's loss.
Read more →-BNR
Mar 28, 2023▲ +5.4%on this news
Burning Rock Reports Fourth Quarter and Full Year 2022 Financial Results
Burning Rock Biotech Limited has reported its financial results for the fourth quarter and full year of 2022. While the company experienced a decrease in revenue in Q4 2022 and an increase in net loss compared to the previous year, there was a notable increase in non-GAAP gross profit. Furthermore, the company anticipates a revenue growth of approximately 20% for the full year of 2023.
Read more →-BNR
Jan 18, 2023Burning Rock provides an update on 2022 revenue guidance
Burning Rock Biotech Limited has updated its 2022 revenue guidance, now expecting approximately 10% growth compared to 2021, an increase from the previously estimated 5%. This revision is attributed to better performance in the fourth quarter, particularly in the pharma service segment, which is seeing strong growth. However, the company notes that revenues from its central-lab and in-hospital segments are expected to decline significantly due to Covid-related disruptions. The fourth quarter results, set to be announced in March 2023, remain preliminary and could change as final financial statements are prepared.
Read more →-BNR
Jan 4, 2023▲ +25%on this news
Burning Rock Received FDA Breakthrough Device Designation for its OverC Multi-Cancer Detection Blood Test IRVINE, Calif. Jan.03, 2023 - Burning Rock (NASDAQ/LSE: BNR), a company focused on the application of next generat
Burning Rock has received FDA Breakthrough Device Designation for its OverC Multi-Cancer Detection Blood Test. This designation is awarded to devices that offer more effective treatments or diagnoses for serious conditions. The OverC test demonstrates significant sensitivity and specificity for the early detection of several cancer types, and aims to complement existing cancer screening methods. The company plans to further validate this test through prospective studies involving over 10,000 subjects.
Read more →-BNR
Nov 16, 2022Burning Rock Reports Third Quarter 2022 Financial Results
Burning Rock Reports Third Quarter 2022 Financial Results GUANGZHOU, China, November 16, 2022 Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the Company or Burning Rock ), a company focused on the application of next generation sequencing (NGS) technology in the field
Read more →-BNR
Nov 7, 2022Management s Discussion and Analysis of Financial Condition and Results of Operations Discussion and analysis below are limited to the operations of Burning Rock Biotech Limited ( we or us ). Summary Consolidated Financi
Management s Discussion and Analysis of Financial Condition and Results of Operations Discussion and analysis below are limited to the operations of Burning Rock Biotech Limited ( we or us ). Summary Consolidated Financial and Operating Data The summary unaudited interim conso
Read more →-BNR
Nov 2, 2022▲ +7.4%on this newsshared move
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD BE UNLAWFUL. BUR
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD BE UNLAWFUL. BURNING ROCK BIOTECH LIMITED Admission to Trading on the Lond
Read more →-BNR
Sep 8, 2022Burning Rock Announces Results of 2022 Annual General Meeting
Burning Rock Announces Results of 2022 Annual General Meeting GUANGZHOU, China, September 8, 2022 Burning Rock Biotech Limited (NASDAQ: BNR, the Company or Burning Rock ), a company focusing on the application of next generation sequencing (NGS) technology in the field of preci
Read more →-BNR
Aug 31, 2022▲ +20.6%on this news
Burning Rock Reports Second Quarter 2022 Financial Results
Burning Rock Reports Second Quarter 2022 Financial Results GUANGZHOU, China, August 31, 2022 Burning Rock Biotech Limited (NASDAQ: BNR, the Company or Burning Rock ), a company focused on the application of next generation sequencing (NGS) technology in the field of precision o
Read more →-BNR
Aug 3, 2022Burning Rock Announces 2022 Annual General Meeting to be Held on
Burning Rock Announces 2022 Annual General Meeting to be Held on September 8, 2022 GUANGZHOU, China, August 3, 2022 Burning Rock Biotech Limited (NASDAQ: BNR, the Company or Burning Rock ), a company focusing on the application of next generation sequencing (NGS) technology in
Read more →-BNR
Jul 15, 2022Burning Rock Announces Resignation of Director
Burning Rock Announces Resignation of Director GUANGZHOU, China, July 15, 2022 Burning Rock Biotech Limited (NASDAQ: BNR, the Company or Burning Rock ), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today
Read more →-BNR
Jun 24, 2022Burning Rock Announces Changes to Board Composition
Burning Rock Announces Changes to Board Composition GUANGZHOU, China, June 24, 2022 Burning Rock Biotech Limited (NASDAQ: BNR, the Company or Burning Rock ), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology,
Read more →-BNR
Jun 21, 2022▲ +8.6%on this news· ran to +21% by day 3shared move
Burning Rock Announces US$10 Million Share Repurchase Program
Burning Rock Announces US$10 Million Share Repurchase Program GUANGZHOU, China, June 21, 2022 Burning Rock Biotech Limited (NASDAQ: BNR, the Company or Burning Rock ), a company focused on the application of next generation sequencing (NGS) technology in the field of precision
Read more →-BNR
Jun 21, 2022▲ +8.6%on this news· ran to +21% by day 3shared move
Burning Rock Announces Plan to Pursue An Alternative Listing
Burning Rock Announces Plan to Pursue An Alternative Listing GUANGZHOU, China, June 21, 2022 Burning Rock Biotech Limited (NASDAQ: BNR, the Company or Burning Rock ), a company focused on the application of next generation sequencing (NGS) technology in the field of precision o
Read more →-BNR
May 31, 2022Burning Rock Reports First Quarter 2022 Financial Results
Burning Rock Reports First Quarter 2022 Financial Results GUANGZHOU, China, May 31, 2022 Burning Rock Biotech Limited (NASDAQ: BNR, the Company or Burning Rock ), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncol
Read more →-BNR
Mar 22, 2022▲ +5.3%on this news
Burning Rock Reports Fourth Quarter and Full Year 2021 Financial Results
Burning Rock Reports Fourth Quarter and Full Year 2021 Financial Results GUANGZHOU, China, March 22, 2022 Burning Rock Biotech Limited (NASDAQ: BNR, the Company or Burning Rock ), a company focused on the application of next generation sequencing (NGS) technology in the field o
Read more →-BNR
Dec 28, 2021▼ -5.6%on this news
Burning Rock Announces Results of 2021 Annual General Meeting
Burning Rock Announces Results of 2021 Annual General Meeting GUANGZHOU, China, December 28, 2021 Burning Rock Biotech Limited (NASDAQ: BNR, the Company or Burning Rock ), a company focused on the application of next generation sequencing (NGS) technology in the field of precis
Read more →-BNR
Nov 16, 2021▲ +10.7%on this news· ran to +25% by day 3
Burning Rock Reports Third Quarter 2021 Financial Results
Burning Rock Reports Third Quarter 2021 Financial Results GUANGZHOU, China, November 16, 2021 Burning Rock Biotech Limited (NASDAQ: BNR, the Company or Burning Rock ), a company focused on the application of next generation sequencing (NGS) technology in the field of precision
Read more →-BNR
Aug 31, 2021▼ -6.5%on this news
Burning Rock Reports Second Quarter 2021 Financial Results
Burning Rock Reports Second Quarter 2021 Financial Results GUANGZHOU, China, August 31, 2021 Burning Rock Biotech Limited (NASDAQ: BNR, the Company or Burning Rock ), a company focused on the application of next generation sequencing (NGS) technology in the field of precision o
Read more →-BNR
May 25, 2021Burning Rock Reports First Quarter 2021 Financial Results
Burning Rock Reports First Quarter 2021 Financial Results GUANGZHOU, China, May 25, 2021 Burning Rock Biotech Limited (NASDAQ: BNR, the Company or Burning Rock ), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncol
Read more →-BNR
Mar 11, 2021Burning Rock Reports Fourth Quarter and Full Year 2020 Financial Results
Burning Rock Reports Fourth Quarter and Full Year 2020 Financial Results GUANGZHOU, China, March 11, 2021 Burning Rock Biotech Limited (NASDAQ: BNR, the Company or Burning Rock ), a company focused on the application of next generation sequencing (NGS) technology in the field o
Read more →-BNR
Dec 2, 2020Burning Rock Announces Proposed Registered Secondary Public Offering of American Depositary Shares
Burning Rock Announces Proposed Registered Secondary Public Offering of American Depositary Shares GUANGZHOU, China, December 2, 2020 Burning Rock Biotech Limited (NASDAQ: BNR, the Company or Burning Rock ), a company focused on the application of next generation sequencing (NG
Read more →-BNR
Nov 20, 2020Burning Rock Reports Third Quarter 2020 Financial Results
Burning Rock Reports Third Quarter 2020 Financial Results GUANGZHOU, China, November 20, 2020 Burning Rock Biotech Limited (NASDAQ: BNR, the Company or Burning Rock ), a company focused on the application of next generation sequencing (NGS) technology in the field of precision
Read more →-BNR
Aug 11, 2020Burning Rock Reports Second Quarter 2020 Financial Results
Burning Rock Reports Second Quarter 2020 Financial Results GUANGZHOU, China, August 11, 2020 Burning Rock Biotech Limited (NASDAQ: BNR, the Company or Burning Rock ), a company focused on the application of next generation sequencing (NGS) technology in the field of precision o
Read more →Competitive Position
How BNR ranks across every disease it competes inCompetitive Position is a premium feature
See how BNR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial